Haleon stock outlook tightens after slower third-quarter growth
Published on 11/10/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSHaleon faces slower growth
- Third-quarter organic revenue growth fell short of management expectations.
- Weak cold and flu consumption and a China supply disruption weighed on performance.
- Haleon kept its profit outlook and announced further shareholder returns.
Haleon's third-quarter update points to slower growth in its consumer health business, with softer cold and flu demand and a China supply disruption weighing on performance. The company said its organic revenue growth of 2.6 percent for the three months ended September 30 was below expectations.
The Haleon Q3 trading statement, published on October 29, showed reported revenue of GBP 2.868 billion. Oral Health remained the strongest category, with organic growth of 8.8 percent, while Respiratory Health declined 2.0 percent and Vitamins, Minerals and Supplements slipped 0.5 percent.
Demand and supply pressures persist
Haleon said lower cold and flu consumption led to reduced orders in North America. In China, a raw material classification change affected Centrum products registered as over-the-counter medicines and forced the company to stop importing the affected material until further notice. Haleon said the issue was not related to product quality or safety.
The company now expects full-year 2026 organic revenue growth of around 2.5 percent. It continues to forecast high-single-digit adjusted operating profit growth at constant currency, supported by supply chain productivity and other efficiency measures. Haleon also expects the China issue and an accelerated go-to-market model in Brazil to affect the outlook.
Capital returns remain in focus
Haleon allocated a further GBP 500 million to share buybacks, with completion targeted by the full-year results in February 2027. Management said stronger cash generation gives it room to invest in the business while returning surplus capital to shareholders.
Haleon stock traded at EUR 3.99 on Lang & Schwarz at 13:15:35 CET on Tuesday, November 10, 2026.
Haleon company facts
- Company: Haleon plc
- ISIN: GB00BMX86B70
- Trading venue: Lang & Schwarz
- Price: EUR 3.99 at 13:15:35 CET on November 10, 2026
- Q3 reported revenue: GBP 2.868 billion for the three months ended September 30, 2026
European markets remain an important backdrop for consumer health shares; see the FTSE 100 market overview.
More news and analyses on Haleon stock.
